Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall is the largest gathering of advanced wound care industry and healthcare professiona ...

10 Former MiMedx Employees In Non-Compete Suit Fight Back Against MiMedx Schemes to "Bilk Medicare" and "Incentivize Fraud" in Counterclaims Filed by Mintz Attorneys MARIETTA, Ga., Sept. 11, 2024 /PRNewswire/ -- 10 former employees of MiMedx Group, Inc. (NASDAQ: MDXG) have now filed counterclaims against the placental biologics company in response to a non-compete lawsuit filed by MiMedx earlier this year. Among other allegations, the employee countersuits assert that in some cases that MiMedx engaged in "s ...

Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga., Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company. Jake Heikkinen, a former MiMedx employee, states in the filing that he left the placental biologics company because of "MiMedx's schemes to bilk Medicare and othe ...

Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga., Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company. Caralyn Gargan, a former MiMedx employee, filed the action against MiMedx for "predatory sales practices" and "incentivized fraud, including Medicare fraud." Gargan also formally ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Chase Knickerbocker - Craig-Hallum Capital Group Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Operator Greetings and welcome to the MiMedx Second Quarter ...

Exhibit 99.1 MIMEDX Announces Second Quarter 2024 Operating and Financial Results Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024, at 4:30 PM ET MARIETTA, Ga., July 31, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating and f ...

Product Launch - MiMedx Group Inc announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed for complex wound management in surgical settings [1] - HELIOGEN contains Type I and Type III collagen, mimicking the native composition of structural connective tissue, and is shelf-stable [1] Strategic Expansion - The launch of HELIOGEN represents a strategic initiative to expand the company's surgical footprint, following the successful introduction of two new surgical products in late 2022 [2] - HELIOGEN is the company's first xenograft option and 510(k) cleared product, complementing its existing placental-based solutions in the surgical market [2] Product Features - HELIOGEN is a bovine-derived collagen matrix product indicated for managing moderately to heavily exudating wounds and controlling minor bleeding [3] - The product supports wound healing by allowing cell adhesion and migration into the wound site, and is provided in particulate form to conform to various wound types [3] Company Overview - MiMedx is a pioneer in wound care, with over a decade of experience in helping clinicians manage chronic and hard-to-heal wounds [4] - The company focuses on providing a leading portfolio of products for wound care, burn, and surgical sectors, aiming to be the global leader in healing solutions through innovation [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-279255 ...

Marks MIMEDX's first publication in the 5th most-cited journal in the world About MIMEDX Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process The study evaluated two configurations of PURION processed placental-based allografts for their ability to regulate fibrotic processes as modeled in a physiologically relevant in vitro system. Both dehydrated human amnion chorion membrane (DHACM) and ...

MARIETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced the publication of a peer reviewed study characterizing a potential mechanism by which placental-based allografts modulate the occurrence of scarring and fibrosis in surgical procedures. The article, "Human amniotic membrane modulates collagen production and deposition in vitro" represents the Company's first publication in Nature and can be accessed online here. About MIMEDX Marks ...